771 Paclitaxel and carboplatin as adjuvant treatment in high-risk patients with operable non-small cell lung cancer (NSCLC): A feasibility study conducted by the hellenic cooperative oncology group (HeCOG)

H.Timotheadou; Ch.Christodoulou; Ch.Papakonstantinou; S.Papadopoulos; J.Skrickova; E.Samantas; P.Papakostas; G.Fountzilas

首页> 外文期刊>European Journal of Cancer Supplements >771 Paclitaxel and carboplatin as adjuvant treatment in high-risk patients with operable non-small cell lung cancer (NSCLC): A feasibility study conducted by the hellenic cooperative oncology group (HeCOG)

【24h】

771 Paclitaxel and carboplatin as adjuvant treatment in high-risk patients with operable non-small cell lung cancer (NSCLC): A feasibility study conducted by the hellenic cooperative oncology group (HeCOG)

机译：771紫杉醇和卡铂辅助治疗可手术的非小细胞肺癌（NSCLC）高危患者：由希腊合作肿瘤小组（HeCOG）进行的可行性研究

获取原文

获取外文期刊封面封底 >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《European Journal of Cancer Supplements》 |2003年第5期|共1页
作者
H.Timotheadou; Ch.Christodoulou; Ch.Papakonstantinou; S.Papadopoulos; J.Skrickova; E.Samantas; P.Papakostas; G.Fountzilas;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种
中图分类肿瘤学;
关键词

相似文献

外文文献
中文文献
专利

1. 771 Paclitaxel and carboplatin as adjuvant treatment in high-risk patients with operable non-small cell lung cancer (NSCLC): A feasibility study conducted by the hellenic cooperative oncology group (HeCOG) [J] . H.Timotheadou, Ch.Christodoulou, Ch.Papakonstantinou, European Journal of Cancer Supplements . 2003,第5期

机译：771紫杉醇和卡铂辅助治疗可手术的非小细胞肺癌（NSCLC）高危患者：由希腊合作肿瘤小组（HeCOG）进行的可行性研究
2. Paclitaxel (175 mg/m2) plus carboplatin (6 AUC) versus paclitaxel (225 mg/m2) plus carboplatin (6 AUC) in advanced non-small-cell lung cancer (NSCLC): a multicenter randomized trial. Hellenic Cooperative Oncology Group (HeCOG). [J] . Kosmidis P, Mylonakis N, Skarlos D, Annals of oncology: official journal of the European Society for Medical Oncology . 2000,第7期

机译：紫杉醇（175 mg / m2）加卡铂（6 AUC）与紫杉醇（225 mg / m2）加卡铂（6 AUC）在晚期非小细胞肺癌（NSCLC）中的多中心随机试验。希腊合作肿瘤小组（HeCOG）。
3. Adjuvant dose-dense sequential chemotherapy with epirubicin, CMF and weekly paclitaxel in patients with resected high-risk breast cancer: a Hellenic Cooperative Oncology Group (HeCOG) study. [J] . Papadimitriou CA, Papakostas P, Timotheadou E, Cancer investigation . 2008,第5期

机译：切除高危乳腺癌患者中使用表柔比星，CMF和每周紫杉醇辅助剂量密集的序贯化疗：希腊合作肿瘤小组（HeCOG）的研究。
4. Enumeration and ALK Investigation of Circulating Tumor Cells in Non-Small Cell Lung Cancer (NSCLC) Patients Using an Effective In Vivo Technology, the GILUPI CellCollector? [C] . Klaus Luecke, Lukasz Gasiorowski, Stefanie Herold, International Molecular Medicine Tri-Conference. . 2015

机译：使用有效的体内技术（Gilupi Cellcollector
5. Pre-Treatment Radiomics Models for Clinical Outcomes in Early-Stage Non-Small Cell Lung Cancer (NSCLC) [D] . Shaffer, Nathan Allen. 2021

机译：早期非小细胞肺癌临床结果的预处理辐射瘤模型（NSCLC）
6. Three-arm randomized phase II study of carboplatin and paclitaxel in combination with cetuximab cixutumumab or both for advanced non-small cell lung cancer (NSCLC) patients who will not receive bevacizumab-based therapy: An Eastern Cooperative Oncology Group (ECOG) study (E4508) [O] . Nasser H. Hanna, Suzanne E. Dahlberg, Jill Kolesar, -1

机译：三臂卡铂和紫杉醇联合西妥昔单抗西妥昔单抗或两者联合用于不接受贝伐单抗治疗的晚期非小细胞肺癌（NSCLC）患者的三臂随机II期研究：东方合作肿瘤小组（ECOG）研究（E4508）
7. Three-arm, randomized, phase 2 study of carboplatin and paclitaxel in combination with cetuximab, cixutumumab, or both for advanced non-small cell lung cancer (NSCLC) patients who will not receive bevacizumab-based therapy: An Eastern Cooperative Oncology Group (ECOG) study (E4508) [O] . Hanna Nasser H., Dahlberg Suzanne E., Kolesar Jill M., 2015

机译：三臂，卡铂和紫杉醇联合西妥昔单抗，西妥昔单抗或两者联合用于不接受贝伐单抗治疗的晚期非小细胞肺癌（NSCLC）患者的三阶段随机2期研究：东部合作肿瘤小组（ECOG ）研究（E4508）

771 Paclitaxel and carboplatin as adjuvant treatment in high-risk patients with operable non-small cell lung cancer (NSCLC): A feasibility study conducted by the hellenic cooperative oncology group (HeCOG)

著录项

相似文献

相关主题

期刊订阅